Efficacy and safety of regulating intestinal flora with yiqi-yangxue and tongluo prescriptions in improving left ventricular remodeling and cardiac function in patients with acute coronary syndrome: a randomized, double-blind, placebo-controlled, multicenter clinical trial

Qilu Hospital of Shandong University0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Outpatient or inpatient patients aged 18-74 (including 18 and 74) years;
•2. Meet the Western Medicine diagnostic criteria of ''Guidelines for Rapid Diagnosis and Treatment of Acute Coronary Syndrome (2019)'', the primary disease is acute coronary syndrome, and the condition is relatively stable;
•3. Serum NT-proBNP level increased, aged 18-50 years, NT-proBNP>450ng/L; aged 51-74 years, NT-proBNP>900ng/L;
•4. Patients who have no allergic reaction to the drugs used in this treatment;
•5. Patients who are willing to sign the informed consent form and cooperate with the treatment.

•1. Patients with severe mental disorders;
•2. Patients with other heart diseases;
•3. Patients who are pregnant or breastfeeding;
•4. Patients with liver and kidney damage;
•5. Patients with cerebral hemorrhage, gastrointestinal bleeding and other diseases;
•6. Patients who are unwilling to cooperate with treatment.

发起方